Cambridge, UK, 27th March 2021 – TRx Biosciences is pleased to announce the first IP filing in relation to its novel oral drug delivery platform, which offers a radical approach to drug absorption, transport and tissue targeting.

TRx’s technology platform represents a paradigm shift in the way that oral drug uptake is considered with relevance across multiple therapeutic themes.

TRx CEO, Dr Robin Bannister said “Recent breakthroughs in our research have made the TRx technology platform applicable to a broad range of small molecule drugs for the first time. In-vivo data is demonstrating exactly what we expected – that we can start to consider previously unexploited uptake channels as a novel route to maximising the therapeutic potential of many small molecules as new medicines”.